Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 83.9% on Analyst Downgrade

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s share price fell 83.9% on Monday after BTIG Research lowered their price target on the stock from $55.00 to $15.00. BTIG Research currently has a buy rating on the stock. Tvardi Therapeutics traded as low as $5.65 and last traded at $6.69. 6,316,128 shares changed hands during mid-day trading, an increase of 8,634% from the average session volume of 72,314 shares. The stock had previously closed at $41.60.

Several other research analysts also recently weighed in on the stock. Raymond James Financial began coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They set an “outperform” rating and a $62.00 price target for the company. Piper Sandler downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Saturday, September 27th. Barclays started coverage on shares of Tvardi Therapeutics in a research report on Monday. They set an “overweight” rating and a $61.00 price target for the company. Finally, Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $46.17.

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $80,000. Bank of America Corp DE purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $399,000. 683 Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $4,107,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $43,000. Finally, Slate Path Capital LP purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $16,427,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

The company’s 50 day moving average is $31.63.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.